Following the recommendation for regulatory approval under the European decentralized procedure, Toctino received its first national regulatory approval in the UK.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.